STOCK TITAN

MARIMED (MRMD) Stock Price, News & Analysis

MRMD OTC
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
76 252 sessions, October 23, 2025 to October 23, 2026
Largest daily move
+42.8% close of December 12, 2025
1-year change
-63% closing prices, October 23, 2025 to October 23, 2026
1-month change
-28.6% closing prices, September 23, 2026 to October 23, 2026

Company Description

MariMed Inc. (MRMD) is described as a multi-state cannabis operator and cannabis consumer packaged goods company. According to its public communications, MariMed focuses on developing and managing cultivation, production, and retail facilities and on building a portfolio of branded cannabis products that are distributed across multiple U.S. markets. The company highlights a mission of improving lives every day through its cannabis offerings.

Business focus and operations

MariMed states that it develops and manages what it calls state-of-the-art cultivation, production, and retail facilities. These facilities support both wholesale and retail channels. The company reports owning or managing revenue-generating operations in several U.S. states, with a network that includes dispensaries and cultivation and processing facilities.

In its disclosures, MariMed emphasizes a strategy it refers to as "Expand the Brand," which centers on growing top-selling cannabis brands and expanding their distribution into new markets. The company also notes that it has used managed services and licensing agreements in certain states to distribute its brands and, in some cases, manage third-party facilities.

Brand portfolio

A core part of MariMed’s identity is its award-winning portfolio of cannabis brands. Across its news releases, the company repeatedly cites the following brands as part of its lineup:

  • Betty’s Eddies™ – all-natural cannabis fruit chews that are described as handcrafted for specific health and wellness effects. The brand highlights varieties associated with themes such as restful nights, stress relief, energy, pain relief, and other end-effects.
  • Bubby’s Baked™ – a line of cannabis baked goods referenced as part of MariMed’s edibles portfolio.
  • Vibations™ – a hydrating drink mix positioned as a cannabis beverage brand. MariMed notes that Vibations is among the top-selling cannabis beverage brands in certain states and that a hemp-derived THC version is planned for broader distribution.
  • InHouse™ – a value-priced line of cannabis flower, vapes, and gummies. InHouse is described as offering high-quality products intended to be enjoyable for a range of cannabis consumers.
  • Nature’s Heritage™ – a brand associated with cannabis flower, pre-rolls, vapes, and other products, including a vegan pill product under the MycroDose by Nature’s Heritage name.

MariMed’s communications describe these brands as trusted and recognized by consumers in the markets where they are sold. The company also notes that it seeks to introduce these brands into additional states through licensing and distribution agreements.

Geographic footprint and market approach

MariMed reports that it operates as a multi-state cannabis operator. It has stated that it owns or manages revenue-generating operations in several states, including dispensaries and cultivation and processing facilities. The company has also discussed entering or exiting individual state markets based on strategic reviews and financial considerations.

For example, MariMed has announced a strategic exit from the Missouri market, where it had managed another licensed operator’s facility and distributed certain brands under a managed services and licensing agreement. At the same time, it has highlighted growth initiatives in other states, such as expanding branded product distribution into markets like Maine, Pennsylvania, and New York through licensing and managed services arrangements.

Hemp-derived THC initiatives

In addition to its activities in state-legal cannabis markets, MariMed has announced plans to participate in the hemp-derived THC segment. The company has described manufacturing and distribution agreements that will allow it to introduce hemp-derived THC versions of its beverage and edibles brands, including Vibations and Betty’s Eddies, into new markets. It has also stated that it established a business unit, MMA Hemp Inc., to operate its hemp-derived THC activities.

Financial reporting and metrics

MariMed regularly reports financial results through press releases and SEC filings. In its earnings communications, the company discusses revenue, gross margin, net income or loss, and non-GAAP measures such as Adjusted EBITDA and non-GAAP gross margin. Management explains that these non-GAAP metrics are used internally to assess operating performance and to compare results across periods, and that they exclude items such as depreciation and amortization, stock-based compensation, acquisition-related expenses, and certain other adjustments.

The company notes that these non-GAAP measures are intended as supplements to GAAP results and that calculations may differ from those used by other companies. It also cautions that forward-looking statements in its releases are subject to risks and uncertainties, and refers readers to its SEC filings for additional information on risk factors.

Community and veteran-focused initiatives

MariMed’s communications highlight several community-oriented and veteran-focused initiatives connected to its brands and retail operations. For example, the InHouse brand has organized the "Help on the Homefront" campaign, which offers qualifying veterans the chance to receive funds to help offset housing costs or home improvements in selected markets where MariMed operates retail dispensaries.

Another initiative involves a U.S. Army veteran and customer of a Thrive-branded dispensary, whose experience with medical cannabis inspired an original song. MariMed has featured this song in its dispensaries and tied it to support for a nonprofit organization that works with veterans and songwriters. These activities are presented by the company as part of its broader commitment to serving local communities and supporting veterans.

Regulatory and policy context

MariMed has publicly commented on significant regulatory developments affecting the cannabis industry. In one statement, the company commended the reclassification of cannabis as a Schedule III drug in the United States, describing it as a historic reform. MariMed’s commentary notes potential implications such as recognition of medical uses, reduced tax burdens for compliant state-legal operators, and the possibility of expanded accredited medical research into cannabis-derived medications.

In its forward-looking statements disclaimers, the company acknowledges that changes in law, enforcement, and the economic environment can affect its operations, and it points investors to its SEC reports for more detailed discussions of these risks.

Positioning within the cannabis industry

Across its news releases, MariMed characterizes itself as a multi-state cannabis operator and cannabis consumer packaged goods company with a focus on branded products. The company emphasizes its strategy of owning and expanding top-selling brands, using both company-owned facilities and partnerships such as licensing and managed services agreements to reach additional markets.

According to its own descriptions, MariMed aims to grow by increasing wholesale and retail distribution of its brands, entering new state markets where regulations permit, and extending its portfolio into adjacent areas such as hemp-derived THC products. At the same time, it has indicated that it evaluates individual markets and may exit those where it does not see sufficient opportunity relative to the resources required.

Stock Performance

$0.0528
-5.71%
0.00
Last updated: October 23, 2026 at 15:58
-63%
Performance 1 year
$21.3M

MARIMED (MRMD) closed at $0.0528 on October 23, 2026. Over the past 12 months, the price has lost 63.0%.

See what a $1,000 investment in MRMD would be worth today

Average down calculator for MRMD

MRMD Metrics & Rankings

Price returns through October 23, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Financial Highlights

MARIMED generated $159.8M in revenue in FY2025, retaining a 36.2% gross margin, operating income reached -$2.8M (-1.8% operating margin), and net income was -$14.5M, reflecting a -9.1% net profit margin. Diluted earnings per share stood at -$0.04. The company generated $7.7M in operating cash flow. The current ratio was 1.00, measuring current assets divided by current liabilities.

$159.8M
Revenue (FY2025)
-$14.5M
Net Income (FY2025)
$7.7M
Operating Cash Flow

Upcoming Events

OCT
28
October 28, 2026 Stock Split

Special Meeting

Virtual special meeting to vote on proposed 1-for-50 to 1-for-100 reverse stock split; webcast at company site; 9:30 AM ET.
NOV
11
November 11, 2026 Earnings

Q3 2026 results

Q3 2026 financial results to be released after market close on Nov 11, 2026; press release and IR webcast posting available.
NOV
12
November 12, 2026 Earnings

Earnings conference call

Management will host a conference call Nov 12, 2026 at 8:00 a.m. EDT; live webcast and playback available on MariMed’s Investor Relations site.
MAR
01
March 1, 2028 Financial

8% note maturity

$2.0M 8% note maturing Mar 2028 (issued under restructuring)
FEB
01
February 1, 2031 Financial

Series B conversion

$6.725M Series B preferred convertible Feb 2031 at $0.25 per share
MAR
01
March 1, 2031 Financial

10% note maturity

$6.0M 10% note maturing Mar 2031 (issued under restructuring)

MARIMED has 6 upcoming scheduled events. The next event, "Special Meeting", is scheduled for October 28, 2026 (in 3 days). 2 of them are earnings releases or calls. 3 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the MRMD stock price.

Short Interest History

Last 12 Months

Short interest in MARIMED (MRMD) currently stands at 1.0 thousand shares, down 97.8% from the previous reporting period, representing 0.0% of the float. Since October 2025, short interest has decreased by 97.2%.

Days to Cover History

Last 12 Months

Days to cover for MARIMED (MRMD) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume.

MRMD Company Profile & Sector Positioning

MARIMED (MRMD) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC.

Investors comparing MRMD often look at related companies in the same sector, including VEXT SCIENCE INC (VEXTF), DECIBEL CANNABIS CO (DBCCF), THE CANNABIST CO HLDG (CBSTF), EARTH SCIENCE TECH INC (ETST), and IANTHUS CAPITAL HLDG (ITHUF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MRMD's relative position within its industry.

Frequently Asked Questions

What is the current stock price of MARIMED (MRMD)?

The current stock price of MARIMED (MRMD) is $0.0528 as of October 23, 2026.

What is the market cap of MARIMED (MRMD)?

The market cap of MARIMED (MRMD) is approximately $21.3M. Learn more about what market capitalization means .

What is the revenue of MARIMED (MRMD) stock?

The FY2025 revenue of MARIMED (MRMD) is $159.8M, from its most recent completed fiscal year.

What is the net income of MARIMED (MRMD)?

The FY2025 net income of MARIMED (MRMD) is -$14.5M, from its most recent completed fiscal year.

What is the earnings per share (EPS) of MARIMED (MRMD)?

The diluted earnings per share (EPS) of MARIMED (MRMD) is -$0.04 for FY2025, its most recent completed fiscal year. Learn more about EPS .

What is the operating cash flow of MARIMED (MRMD)?

The operating cash flow of MARIMED (MRMD) is $7.7M for FY2025, its most recent completed fiscal year. Learn about cash flow.

What is the profit margin of MARIMED (MRMD)?

The net profit margin of MARIMED (MRMD) is -9.1% for FY2025, its most recent completed fiscal year. Learn about profit margins.

What is the operating margin of MARIMED (MRMD)?

The operating profit margin of MARIMED (MRMD) is -1.8% for FY2025, its most recent completed fiscal year. Learn about operating margins.

What is the gross margin of MARIMED (MRMD)?

The gross profit margin of MARIMED (MRMD) is 36.2% for FY2025, its most recent completed fiscal year. Learn about gross margins.

What is the current ratio of MARIMED (MRMD)?

The current ratio of MARIMED (MRMD), current assets divided by current liabilities, was 1.00 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

What is the gross profit of MARIMED (MRMD)?

The gross profit of MARIMED (MRMD) is $57.9M for FY2025, its most recent completed fiscal year.

What is the operating income of MARIMED (MRMD)?

The operating income of MARIMED (MRMD) is -$2.8M for FY2025, its most recent completed fiscal year. Learn about operating income.

What is MariMed Inc.’s core business?

MariMed Inc. describes its core business as operating as a multi-state cannabis operator and cannabis consumer packaged goods company. It develops and manages cultivation, production, and retail facilities and focuses on building and distributing a portfolio of branded cannabis products.

Which cannabis brands does MariMed own or produce?

MariMed highlights several brands in its public communications, including Betty’s Eddies™ fruit chews, Bubby’s Baked™ baked goods, Vibations™ hydrating drink mixes, InHouse™ flower, vapes, and gummies, and Nature’s Heritage™ cannabis products.

How does MariMed expand into new state markets?

The company reports using a mix of company-owned operations, managed services agreements, and licensing agreements to enter new state markets. These arrangements allow MariMed’s brands to be manufactured and distributed by licensed partners in additional states.

What is the purpose of MariMed’s "Expand the Brand" strategy?

MariMed’s "Expand the Brand" strategy, as described in its earnings releases, is to own top-selling cannabis brands and increase their distribution. The company aims to grow wholesale and retail sales by bringing its brand portfolio into more markets where cannabis sales are permitted.

Does MariMed operate in the hemp-derived THC segment?

Yes. MariMed has announced manufacturing and distribution agreements to launch hemp-derived THC versions of its beverage and edibles brands, including Vibations™ and Betty’s Eddies™, and has created MMA Hemp Inc. to manage hemp-derived THC activities.

What types of facilities are associated with MariMed’s operations?

MariMed states that it develops and manages cultivation, production, and retail facilities. It also notes that it has managed a third-party licensed cultivation and processing facility under a managed services agreement in at least one state.

How does MariMed present its financial results?

MariMed issues quarterly earnings press releases and files reports with the SEC. It presents GAAP financial results and also reports non-GAAP metrics such as Adjusted EBITDA, non-GAAP gross margin, and non-GAAP net income or loss, explaining the adjustments used in these measures.

What community and veteran initiatives does MariMed support?

MariMed has described initiatives such as the InHouse "Help on the Homefront" campaign, which offers veterans funds to help with housing or home improvements, and a music-focused project at Thrive dispensaries that supports a nonprofit working with veterans and songwriters.

Has MariMed changed its presence in any state markets?

Yes. MariMed has announced that it completed a strategic review of its Missouri operations and decided to exit that market, ending its management of a third-party licensed operator there and no longer seeking a license transfer.

How does MariMed view recent changes in U.S. cannabis regulation?

In a public statement, MariMed commended the reclassification of cannabis as a Schedule III drug, calling it a significant reform. The company noted potential benefits such as recognition of medical uses, relief from certain federal tax penalties for compliant operators, and support for expanded medical research.